DK222 Study at Hopkins

Not Applicable

Not yet recruiting

• Conditions: Non-Small Cell Lung Cancer; Urothelial Cancer
• Interventions: Drug: [18F]DK222 radiotracer

• Registration Number: NCT07140315
• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary

This Phase 1 clinical trial will test a new drug called \[18F\]DK222 in people with cancer. The goal is to see if the drug is safe, how it spreads through the body, how long it stays in the body, and how much radiation it gives off. \[18F\]DK222 is designed to attach strongly and specifically to a protein called PD-L1, which helps cancer hide from the immune system.

This is a first in human study to collect preliminary safety and toxicity data of \[18F\]DK222.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-08
• Study First Submitted: 2025-08-18
• Study First Submitted QC: 2025-08-18
• Last Update Submitted: 2025-08-18
• Study First Posted: 2025-08-24
• Last Update Posted: 2025-08-24
• Study Start: 2025-10-01
• Primary Completion: 2026-10-01
• Study Completion: 2027-02-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

• Subjects must sign informed consent prior to inclusion in this trial.

• Subjects must be ≥18 years of age and competent to give informed consent.

• Subjects must be diagnosed with histologically confirmed NSCLC or UC and eligible for anti-PD(L)-1 therapy.

• PD-L1 immunohistochemistry result using a Clinical Laboratory Improvement Amendments (CLIA) assay must be available or if not available then sufficient tissue must be available to perform PD-L1 testing.

• Subjects must score at least 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.

• Subjects must have adequate organ function as defined by the following laboratory values (determined within 28 days prior to randomization/registration) or as deemed not clinically significant by physician on record:

  • White blood cells (WBC) ≥ 2000 /μL
  • Absolute neutrophil count (ANC) ≥ 1500 /μL
  • Platelets ≥ 100 x103 /μL
  • Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L
  • Serum creatinine ≤ 1.5 times upper limit of normal (ULN) or creatinine clearance greater than or equal to 60 ml/min (using the Cockcroft-Gault formula)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times ULN
  • Bilirubin ≤ 1.5 times ULN (Except patients with the Gilbert Syndrome, for whom a maximum of ≤ 3.0 mg/dL is acceptable)

• Women of childbearing potential (WOCBP) should have a negative serum pregnancy test within 24 hours prior to receiving the first administration [18F]DK222. Women with non-childbearing potential may be included if either surgically sterile or have been postmenopausal for ≥ 1 year.

• WOCBP and men who are sexually active with WOCBP must agree to use appropriate method(s) of contraception.

Exclusion Criteria

• Prior treatment, in either de novo disease or during this recurrence, with an anti-PD-L1 or anti-PD-L2 antibody. A minimum of 4 month washout period is required for patients treated with anti-PD-L1 or anti-PD-L2 therapy. Patients with disease that was previously treated with anti-PD-1, anti-PD-L1, anti-PD-L2 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, but now have a new recurrence, would be eligible.
• Subjects who have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 1 or better from the adverse events due to previous cancer therapy.
• Treatment with corticosteroids in an increasing dosage in the 7 days prior to the first administration of anti-PD1. (A stable or decreasing dosage of ≤ 10 mg dexamethasone or equivalent is allowed. In addition, inhaled or topical steroids and adrenal replacement doses are permitted in the absence of active autoimmune disease.)
• A severe hypersensitivity reaction to prior treatment with a monoclonal antibody, or known hypersensitivity to study drugs components.
• Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the patients to receive protocol therapy.
• Women of childbearing potential with a positive serum or urine pregnancy test (minimum sensitivity 10 IU/L or equivalent units of HCG) within 24 hours prior to the start of imaging.
• Breastfeeding women.
• Inability to comply with other requirements of the protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
[18F]DK222 radiotracer	[18F]DK222 radiotracer	The study is an open label, single-arm study designed to evaluate the safety and diagnostic performance of \[18F\]DK222 radiotracer in NSCLC and UC participants. Participants will undergo a PET-CT scan after \[18F\]DK222 is injected into the participant's vein an intravenous line. This is the imaging procedure to assess where \[18F\]DK222 has accumulated in the body.

Primary Outcome Measures

Name	Time	Method
Safety of [18F]DK222 as assessed by number of grade 3-5 adverse events	Once up to 10 days post radiotracer injection	Any grade 3-5 toxicity attributed to \[¹⁸F\]DK222 administration will be considered as not meeting the safety endpoint. All adverse events (AEs) will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Secondary Outcome Measures

Name	Time	Method
Tolerability of [18F]DK222 as assessed by number of grade 3-5 adverse events	Once up to 10 days post radiotracer injection	. Any grade 3-5 toxicity attributed to \[¹⁸F\]DK222 administration will be considered as not meeting the tolerability endpoint. All adverse events (AEs) will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Trial Locations

Locations (1)

Johns Hopkins Hospital; 🇺🇸 Baltimore, Maryland, United States